[Clinical and immunological studies of an experimental series of vaccines against hepatitis B].
Two experimental lots of hepatitis B vaccine were prepared by purification of HBsAg from human plasma, inactivation at 100 degrees C for 2 min and at 37 degrees C for 72 hours with formalin in a concentration of 1:4000. The former lot comprises purified HBsAg (40 mg/ml) adsorbed with 0.32 mg % Al(OH)3, the latter consists of purified HBsAg stabilized with 0.1% human albumin and adsorbed with 1 mg% Al(OH)3. The immune response after vaccination with the first lot was observed in 54.54% of the vaccinees. The second vaccine after 3 administrations of 80 micrograms/ml each produced a very good primary and a very good secondary immune response. Both vaccines are nonreactogenic and well tolerated by the vaccinees.
D000818:Animals; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization; D007117:Immunization, Secondary; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000302:isolation & purification
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014761:Viral Hepatitis Vaccines
Klinicheskie i immunologicheskie issledovaniia éksperimental'nykh seriĭ vaktsiny protiv gepatita B.